As previously published [17, 20], testing for BCR::ABL1 fusion in patients with known BCR::ABL1-negative MPN was prompted by new-onset leukocytosis, whereas testing for driver mutations in patients with known CML was prompted by new-onset thrombocytosis. This evidence concerns the gene ABL1 and myeloproliferative disorder.